Cargando…
A Nationwide Antenatal Human T-Cell Leukemia Virus Type-1 Antibody Screening in Japan
Japan has been running a nationwide antenatal human T-cell leukemia virus type-1 (HTLV-1) antibody screening program since 2010 for the prevention of HTLV-1 mother-to-child transmission. As part of the program, pregnant women are invited to take an HTLV-1 antibody screening test, usually within the...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7160230/ https://www.ncbi.nlm.nih.gov/pubmed/32328047 http://dx.doi.org/10.3389/fmicb.2020.00595 |
_version_ | 1783522720522174464 |
---|---|
author | Itabashi, Kazuo Miyazawa, Tokuo Sekizawa, Akihiko Tokita, Akifumi Saito, Shigeru Moriuchi, Hiroyuki Nerome, Yasuhito Uchimaru, Kaoru Watanabe, Toshiki |
author_facet | Itabashi, Kazuo Miyazawa, Tokuo Sekizawa, Akihiko Tokita, Akifumi Saito, Shigeru Moriuchi, Hiroyuki Nerome, Yasuhito Uchimaru, Kaoru Watanabe, Toshiki |
author_sort | Itabashi, Kazuo |
collection | PubMed |
description | Japan has been running a nationwide antenatal human T-cell leukemia virus type-1 (HTLV-1) antibody screening program since 2010 for the prevention of HTLV-1 mother-to-child transmission. As part of the program, pregnant women are invited to take an HTLV-1 antibody screening test, usually within the first 30 weeks of gestation, during regular pregnancy checkups. Pregnant women tested positive on the antibody screening test undergo a confirmatory test, either western blotting or line immunoassay. In indeterminate case, polymerase chain reaction (PCR) is used as a final test to diagnose infection. Pregnant women tested positive on a confirmatory or PCR test are identified as HTLV-1 carriers. As breastfeeding is a predominant route of postnatal HTLV-1 mother-to-child transmission, exclusive formula feeding is widely used as a postnatal preventive measure. Although there is insufficient evidence that short-term breastfeeding during ≤3 months does not increase the risk of mother-to-child transmission compared to exclusive formula feeding, this feeding method is considered if the mother is eager to breastfeed her child. However, it is important that mothers and family members fully understand that there is an increase in the risk of mother-to-child transmission when breastfeeding would be prolonged. As there are only a few clinical studies on the protective effect of frozen-thawed breastmilk feeding on mother-to-child transmission of HTLV-1, there is little evidence to recommend this feeding method. Further study on the protective effects of these feeding methods are needed. It is assumed that the risk of anxiety or depression may increase in the mothers who selected exclusive formula feeding or short-term breastfeeding. Thus, an adequate support and counseling for these mothers should be provided. In addition to raising public awareness of HTLV-1 infection, epidemiological data from the nationwide program needs to be collected and analyzed. In most cases, infected children are asymptomatic, and it is necessary to clarify how these children should be followed medically. |
format | Online Article Text |
id | pubmed-7160230 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-71602302020-04-23 A Nationwide Antenatal Human T-Cell Leukemia Virus Type-1 Antibody Screening in Japan Itabashi, Kazuo Miyazawa, Tokuo Sekizawa, Akihiko Tokita, Akifumi Saito, Shigeru Moriuchi, Hiroyuki Nerome, Yasuhito Uchimaru, Kaoru Watanabe, Toshiki Front Microbiol Microbiology Japan has been running a nationwide antenatal human T-cell leukemia virus type-1 (HTLV-1) antibody screening program since 2010 for the prevention of HTLV-1 mother-to-child transmission. As part of the program, pregnant women are invited to take an HTLV-1 antibody screening test, usually within the first 30 weeks of gestation, during regular pregnancy checkups. Pregnant women tested positive on the antibody screening test undergo a confirmatory test, either western blotting or line immunoassay. In indeterminate case, polymerase chain reaction (PCR) is used as a final test to diagnose infection. Pregnant women tested positive on a confirmatory or PCR test are identified as HTLV-1 carriers. As breastfeeding is a predominant route of postnatal HTLV-1 mother-to-child transmission, exclusive formula feeding is widely used as a postnatal preventive measure. Although there is insufficient evidence that short-term breastfeeding during ≤3 months does not increase the risk of mother-to-child transmission compared to exclusive formula feeding, this feeding method is considered if the mother is eager to breastfeed her child. However, it is important that mothers and family members fully understand that there is an increase in the risk of mother-to-child transmission when breastfeeding would be prolonged. As there are only a few clinical studies on the protective effect of frozen-thawed breastmilk feeding on mother-to-child transmission of HTLV-1, there is little evidence to recommend this feeding method. Further study on the protective effects of these feeding methods are needed. It is assumed that the risk of anxiety or depression may increase in the mothers who selected exclusive formula feeding or short-term breastfeeding. Thus, an adequate support and counseling for these mothers should be provided. In addition to raising public awareness of HTLV-1 infection, epidemiological data from the nationwide program needs to be collected and analyzed. In most cases, infected children are asymptomatic, and it is necessary to clarify how these children should be followed medically. Frontiers Media S.A. 2020-04-09 /pmc/articles/PMC7160230/ /pubmed/32328047 http://dx.doi.org/10.3389/fmicb.2020.00595 Text en Copyright © 2020 Itabashi, Miyazawa, Sekizawa, Tokita, Saito, Moriuchi, Nerome, Uchimaru and Watanabe. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Microbiology Itabashi, Kazuo Miyazawa, Tokuo Sekizawa, Akihiko Tokita, Akifumi Saito, Shigeru Moriuchi, Hiroyuki Nerome, Yasuhito Uchimaru, Kaoru Watanabe, Toshiki A Nationwide Antenatal Human T-Cell Leukemia Virus Type-1 Antibody Screening in Japan |
title | A Nationwide Antenatal Human T-Cell Leukemia Virus Type-1 Antibody Screening in Japan |
title_full | A Nationwide Antenatal Human T-Cell Leukemia Virus Type-1 Antibody Screening in Japan |
title_fullStr | A Nationwide Antenatal Human T-Cell Leukemia Virus Type-1 Antibody Screening in Japan |
title_full_unstemmed | A Nationwide Antenatal Human T-Cell Leukemia Virus Type-1 Antibody Screening in Japan |
title_short | A Nationwide Antenatal Human T-Cell Leukemia Virus Type-1 Antibody Screening in Japan |
title_sort | nationwide antenatal human t-cell leukemia virus type-1 antibody screening in japan |
topic | Microbiology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7160230/ https://www.ncbi.nlm.nih.gov/pubmed/32328047 http://dx.doi.org/10.3389/fmicb.2020.00595 |
work_keys_str_mv | AT itabashikazuo anationwideantenatalhumantcellleukemiavirustype1antibodyscreeninginjapan AT miyazawatokuo anationwideantenatalhumantcellleukemiavirustype1antibodyscreeninginjapan AT sekizawaakihiko anationwideantenatalhumantcellleukemiavirustype1antibodyscreeninginjapan AT tokitaakifumi anationwideantenatalhumantcellleukemiavirustype1antibodyscreeninginjapan AT saitoshigeru anationwideantenatalhumantcellleukemiavirustype1antibodyscreeninginjapan AT moriuchihiroyuki anationwideantenatalhumantcellleukemiavirustype1antibodyscreeninginjapan AT neromeyasuhito anationwideantenatalhumantcellleukemiavirustype1antibodyscreeninginjapan AT uchimarukaoru anationwideantenatalhumantcellleukemiavirustype1antibodyscreeninginjapan AT watanabetoshiki anationwideantenatalhumantcellleukemiavirustype1antibodyscreeninginjapan AT itabashikazuo nationwideantenatalhumantcellleukemiavirustype1antibodyscreeninginjapan AT miyazawatokuo nationwideantenatalhumantcellleukemiavirustype1antibodyscreeninginjapan AT sekizawaakihiko nationwideantenatalhumantcellleukemiavirustype1antibodyscreeninginjapan AT tokitaakifumi nationwideantenatalhumantcellleukemiavirustype1antibodyscreeninginjapan AT saitoshigeru nationwideantenatalhumantcellleukemiavirustype1antibodyscreeninginjapan AT moriuchihiroyuki nationwideantenatalhumantcellleukemiavirustype1antibodyscreeninginjapan AT neromeyasuhito nationwideantenatalhumantcellleukemiavirustype1antibodyscreeninginjapan AT uchimarukaoru nationwideantenatalhumantcellleukemiavirustype1antibodyscreeninginjapan AT watanabetoshiki nationwideantenatalhumantcellleukemiavirustype1antibodyscreeninginjapan |